ReviewCurrent opinion in hematology2012
Hematopoietic stem cell transplantation for severe congenital neutropenia.
Review in Current opinion in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.Bone marrow transplantation · 2015Guideline
- CRISPR-based therapeutic genome editing for inherited blood disorders.Nature reviews. Drug discovery · 2025Review
- A large cohort from an immunology reference center and an algorithm for the follow-up of chronic neutropenia.Journal of clinical immunology · 2024Article
- Review
- Dental Abnormalities in Pediatric Patients Receiving Chemotherapy.Journal of clinical medicine · 2024Article
- Successful Bone Marrow Transplantation in a Patient with Acute Myeloid Leukemia Developed from Severe Congenital Neutropenia Using Modified Chemotherapy and Conditioning Regimen for Leukemia.Hematology reports · 2024Article
- Reduced toxicity matched sibling bone marrow transplant results in excellent outcomes for severe congenital neutropenia.Frontiers in immunology · 2024Article
- Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia.Frontiers in immunology · 2024Article
- Neutropenic ulcers in oncology: terminology, diagnosis, and management.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Ex Vivo Expansion and Homing of Human Cord Blood Hematopoietic Stem Cells.Advances in experimental medicine and biology · 2023Article
- Diagnosis and therapeutic decision-making for the neutropenic patient.Hematology. American Society of Hematology. Education Program · 2021Article
- Identification of novelCold Spring Harbor molecular case studies · 2018Review
- Elastase inhibitors as potential therapies forJournal of leukocyte biology · 2017Article
- Periodontal and other oral manifestations of immunodeficiency diseases.Oral diseases · 2017Review
- [Advances in research on childhood neutropenia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Review
- Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.Leukemia & lymphoma · 2016Article
- Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.Current opinion in pediatrics · 2015Review
- Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood.Frontiers in pediatrics · 2015Review
- Inherited bone marrow failure syndromes in adolescents and young adults.Annals of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewHematopoietic stem cell transplantation (HCT) is the only curative option for patients with severe congenital neutropenia (SCN). Transplant success is dependent on identifying at-risk patients and proceeding to transplant before the development of severe infections or malignant transformation. This review focuses on recent advancements in risk stratification of SCN patients, indications for HCT, and review of published transplant studies. RECENT
findingsPatients with poor neutrophil response despite high doses of granulocyte colony-stimulating factor (G-CSF) are at greatest risk for malignant transformation. Other studies demonstrate elevated risk with mutations in the G-CSF receptor gene and a specific mutation in the ELANE gene. These patients are at high-risk of sepsis or leukemia development and should proceed to transplant with best available donor. As recent published studies demonstrate, HCT is highly successful in patients without leukemia and, therefore, may be considered in selected low-risk patients given the life-long risk of malignancy and infection. SUMMARY: The decision whether to proceed to HCT in healthy patients maintained on G-CSF is difficult. As transplant-related mortality continues to decrease, the role of transplant in SCN is likely to expand to more patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.